BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
RBC Capital downgraded BioCryst Pharmaceuticals (BCRX) to 'Sector Perform' and cut its price target to $11, citing competition from Pharvaris's (PHVS) strong HAE therapy data. BCRX shares fell 8%, heading for a fifth straight day of losses. Orladeyo's revenue is expected to drop to $400M-$450M due to competition, though Navenibart's Phase 3 data is awaited in 2027.
How this was made
The 30-second read
Why it matters
The downgrade reflects concerns over market share loss to Pharvaris, driving the stock lower.
Market read
Analyst downgrade and target cut create immediate sell pressure on BCRX.
What to watch
Potential revenue from Orladeyo remains strong in 2026 despite competition.
Background
RBC Capital cited strong late‑stage data from competitor Pharvaris, prompting a downgrade of BioCryst.
Ticker impact
RBC downgraded BioCryst to Sector Perform, cut price target to $11 and shares fell 8% to around $8.
Further downside pressure likely unless new catalyst emerges.
Downgrade is fresh news; market has already reacted with an 8% drop, suggesting continued sell pressure.
Market effects
Hereditary angioedema biotech sector may see heightened scrutiny as competitor data emerges.
U.S. biotech investors may reassess exposure to HAE therapies.
Limited to niche biotech space; no broad market effect.
Counterpoint
If BioCryst's second HAE drug Navenibart shows strong data, the downgrade could be overblown.
Key entities
- companyBioCryst Pharmaceuticals
US‑listed biotech developing HAE therapies.
- companyPharvaris
Competitor with late‑stage HAE drug Deucrictibant XR.
